- Home
- Equities - Stocks - Shares
- Company Press Releases
- Nykode Therapeutics To Present At Two Upcoming Investor Conferences In November
Nykode Therapeutics to present at two upcoming investor conferences in November
07 Nov 2022 08:00 CET
Issuer
NYKODE THERAPEUTICS ASA
Oslo, Norway, November 7, 2022 – Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that its Chief Executive
Officer, Michael Engsig, and Chief Business Officer & Co-founder, Agnete
Fredriksen, will present and host 1x1 meetings at two upcoming investor
conferences in November.
Presentation Details
Credit Suisse Annual Healthcare Conference
Date: Tuesday, November 8, 2022
Jefferies London Healthcare Conference
Date: Thursday, November 17, 2022
Slides of both presentations can be accessed in the Investors section of the
Company’s website here:
https://nykode.com/investors/financial-reports-and-presentations/
A live and archived webcast of the Jefferies presentation will also be
available.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode’s modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which are essential for inducing
rapid, strong and long-lasting antigen specific immune responses and eliciting
efficacious clinical responses.
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase 2 trial
for the treatment of cervical cancer; and VB10.NEO, an individualized cancer
neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of
the Roche Group. Additionally, Nykode is conducting a Phase 1/2 trial with
next-generation COVID-19 vaccine candidates.
The Company’s partnerships include Genentech within oncology, a multi-target
collaboration with Regeneron within oncology and infectious diseases and a
collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine
development.
Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics may be found at
http://www.nykode.com.
Contact for Nykode Therapeutics ASA:
Chief Business Officer, Agnete Fredriksen
Nykode Therapeutics ASA
IR@nykode.com
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
Solebury Strategic Communications
Shabnam Bashir
sbashir@soleburystrat.com
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.
More information:
Access the news on Oslo Bors NewsWeb site
Source
Nykode Therapeutics ASA
Provider
Oslo Børs Newspoint
Company Name
NYKODE THERAPEUTICS ASA
ISIN
NO0010714785
Symbol
NYKD
Market
Oslo Børs